Trimbos Jason B
Department of Gynecology, Leiden University Medical Center, Albinusdreef 2, Room K6-19, 2333AA Leiden, The Netherlands.
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:60-70. doi: 10.1016/j.bpobgyn.2016.10.001. Epub 2016 Oct 8.
The treatment of early-stage (stages I-IIA) ovarian carcinoma is predominantly surgical, and the surgical staging is the most relevant step in the treatment of this disease. The significance of surgical staging is twofold. First, proper staging distinguishes between 'real' early-stage ovarian carcinoma and 'perhaps' early-stage disease. The latter carries an appreciable likelihood of unappreciated residual disease in 16-42% of cases. Second, there is solid proof that proper surgical staging is an independent prognostic factor for improved disease-free and overall survival in early-stage ovarian carcinoma. In this chapter, the relevance of various staging steps is discussed and surgical guidelines are given. The indication for adjuvant chemotherapy after surgery is closely related to the adequacy of surgical staging. Adjuvant chemotherapy only works in patients in whom surgical staging was inadequate and who, thus, remain with a certain risk of unnoticed residual intraperitoneal or retroperitoneal tumour spread. Moreover, there is no indication that adjuvant chemotherapy is of any value after an adequate, comprehensive staging procedure. Controversies and misunderstandings on this important issue are discussed.
早期(Ⅰ - ⅡA期)卵巢癌的治疗主要是手术治疗,手术分期是该病治疗中最关键的步骤。手术分期的意义有两方面。首先,恰当的分期能区分“真正的”早期卵巢癌和“可能的”早期疾病。后者在16% - 42%的病例中存在未被发现的残留病灶的明显可能性。其次,有确凿证据表明,恰当的手术分期是早期卵巢癌患者无病生存期和总生存期改善的独立预后因素。在本章中,将讨论各种分期步骤的相关性并给出手术指南。术后辅助化疗的指征与手术分期的充分性密切相关。辅助化疗仅对手术分期不充分、因而仍有一定腹膜内或腹膜后肿瘤未被发现的残留扩散风险的患者有效。此外,没有迹象表明在充分、全面的分期程序后辅助化疗有任何价值。本章将讨论关于这个重要问题的争议和误解。